Clinical trials: GENE EXPRESSION
- Condition GENE EXPRESSION
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Infections, Respiratory Syncytial Virus
Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression
This study is to determine danirixin (GSK1325756) concentrations required to inhibit neutrophil activation in blood obtained from Respiratory Syncytial Virus (RSV)-infected children <2 years and healthy adults.
- Trial name
- NCT02201303
- Testing
- Danirixin, CXCL1
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bordetella Pertussis, Whooping Cough
Impact of Bacterial Expression and Immune Response in the Severity of Pertussis
The resurgence of pertussis is associated with an evolutionary mechanism under the pressure of current acellular vaccines, with a possible impact on vaccine effectiveness and disease expression.
- Trial name
- PERT-SEVEREII (NCT05897879)
- Testing
- Nasopharyngeal swab, Blood samples
- Where
- 14 sites in France
- Volunteers
- 210 people
- Sponsor
- Institut Pasteur
Hepatocellular Carcinoma
Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma
Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these.
- Trial name
- NCT00911196
- Testing
- Retrospective analysis of already archived samples
- Where
- 3 sites in Taiwan, Thailand
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Breast Milk Collection
Human Milk Sample Composition in Israeli Mothers and Correlation With Their Diet
The study will collect human milk from 100 mother of term infants 2-3m after delivery and from 50 mothers of preterm infants 14 and 30 days after delivery.
- Trial name
- NCT02596295
- Where
- Israel
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Enzymotec
Duchenne Muscular Dystrophy (DMD)
Safety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients
The primary objective of this study is to evaluate the safety and tolerability of SPOT-03 administered by intravenous (IV) infusion to DMD patients.
- Trial name
- NCT07188012
- Testing
- SPOT-03
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Siponuoyin Biotechnology Co Ltd
Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)
Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients
This study aims to investigate the expression of Melanoma-associated antigen 3 (MAGE-A3), Melanoma-associated antigen C2 (MAGE-C2), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), L antigen family member 1 (LAGE-1)…
- Trial name
- NCT01837511
- Testing
- Data acquisition and analysis
- Where
- 3 sites in Singapore, South Korea
- Volunteers
- 377 people
- Sponsor
- GlaxoSmithKline
Duchenne Muscular Dystrophy
Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients
The specific aim of this Phase I/II study is to assess the safety of intravenous administered Morpholino oligomer directed against exon 51 (AVI-4658 PMO).
- Trial name
- NCT00844597
- Testing
- AVI-4658 for Injection
- Where
- 2 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- Sarepta Therapeutics, Inc.
Learning Disorder, Specific, Learning Disability
Examining the Effect of a Digital MD for Cognitive and Musical Training + Reduced Conventional SOC on the Reading and Writing Skills of Pediatric Participants With a Specific Learning Disability With Reading and/or Written Expression Deficit vs a Control Group Receiving Conventional SOC.
Poppins-02 is a multicentric randomized non-inferiority study examining the effect of the digital medical device Poppins Clinical for cognitive and musical training in addition to bi-monthly speech and reading therapy sessions on…
- Conditions
- Learning Disorder, Specific, Learning Disability, Specific Learning Disorder, With Impairment in Reading, Dyslexia
- Trial name
- POPPINS-02 (NCT06592911)
- Testing
- Poppins Clinical
- Where
- 2 sites in France
- Volunteers
- 306 people
- Sponsor
- Poppins
Newborns, Breast Milk Expression
Newborns Supplemented With Gentle-UHT Donor Milk
This study evaluates the effects of providing breastfeeding mothers with Gentle-UHT donor human milk (GHM) after discharge to bridge the gap during delayed onset lactation, to support an exclusive human milk diet and continued…
- Trial name
- NCT04492579
- Testing
- Gentle-UHT donor human milk supplementation
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- LactaLogics, Inc
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell
A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
The primary purpose of this non-interventional, multinational study is to assess the feasibility of assessing PD-L1 protein expression on cytological samples as a surrogate for histological samples obtained from participants with…
- Trial name
- NCT03092739
- Testing
- PD-L1 Immunocytochemistry (ICC), PD-L1 Immunohistochemistry (IHC)
- Where
- 8 sites in Czechia, Germany and 4 more
- Volunteers
- 184 people
- Sponsor
- Hoffmann-La Roche
Duchenne Muscular Dystrophy
Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients
This study is designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of AVI-4658 (eteplirsen) in both 50.0 mg/kg and 30.0 mg/kg doses administered over 24 weeks in subjects diagnosed with Duchenne…
- Trial name
- NCT01396239
- Testing
- AVI-4658 (Eteplirsen)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sarepta Therapeutics, Inc.
Duchenne Muscular Dystrophy
A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74
This is a gene transfer therapy study evaluating the safety of and delandistrogene moxeparvovec dystrophin protein expression from delandistrogene moxeparvovec following therapeutic plasma exchange (plasmapheresis) in ambulatory…
- Trial name
- HORIZON (NCT06597656)
- Testing
- delandistrogene moxeparvovec, Plasmapheresis
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Sarepta Therapeutics, Inc.
Graft Rejection, Lung Disease
Lung Allograft Rejection Gene Expression Observational (LARGO) Study
The objective of the LARGO Study protocol is to collect peripheral blood samples, select associated lung biopsy pathology slides, and clinical data from lung transplant recipients to perform molecular analyses in association with…
- Trial name
- LARGO (NCT00751309)
- Testing
- Non-interventional
- Where
- 20 sites in United States, Austria and 3 more
- Volunteers
- 2,044 people, healthy volunteers welcome
- Sponsor
- XDx
Multiple Sclerosis
ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change certain substances (cells) found in the…
- Trial name
- Cylex (NCT00618267)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Biogen
Diabetes, Diabetes Mellitus, Type 1
Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period
This study is conducted in the United States of America (USA). The aim of this study is to assess longitudinal variation of immune biomarkers in subjects with type 1 diabetes (T1D), type 2 diabetes (T2D) and healthy, non-diabetic…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01900834
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Neuroblastoma, Pheochromocytoma
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
This is a prospective Phase 2 study being performed to document the relationship between 18F-mIBG positron emission tomography (PET) findings in subjects, and expression of the norepinephrine transporter.
- Conditions
- Neuroblastoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT06233903
- Testing
- 18F-mFBG
- Where
- United States
- Sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Non-Hodgkin's Disease
An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas
The purpose of this study is to determine whether Nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-Hodgkin's lymphomas with CD30 expression that have not responded…
- Trial name
- CheckMate 436 (NCT02581631)
- Testing
- Nivolumab, Brentuximab Vedotin
- Where
- 27 sites in United States, Canada and 4 more
- Volunteers
- 145 people
- Sponsor
- Bristol-Myers Squibb
Cutaneous Melanoma
Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes
The EXPAND Registry Study follows patients with cutaneous melanoma who have had the DecisionDx-Melanoma gene expression assay performed as part of their clinical care.
- Trial name
- EXPAND (NCT02355587)
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Castle Biosciences Incorporated
X-Linked Myotubular Myopathy
A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition
XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness.
- Trial name
- EXCEL (NCT06581146)
- Testing
- No Intervention
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 50 people
- Sponsor
- Astellas Gene Therapies
Duchenne Muscular Dystrophy
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
Cohort 8 (non-ambulatory participants) is currently enrolling new participants. Enrollment for Cohorts 1 through 7 has been completed.
- Trial name
- ENDEAVOR (NCT04626674)
- Testing
- delandistrogene moxeparvovec
- Where
- 12 sites in United States
- Volunteers
- 83 people
- Sponsor
- Sarepta Therapeutics, Inc.